share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  05/08 09:28
Moomoo AI 已提取核心信息
On May 7, 2024, ProSomnus, Inc., a medical technology company, filed for Chapter 11 bankruptcy and entered into a Restructuring Support Agreement (RSA) with its affiliates, subsidiaries, and certain note holders. The RSA outlines a voluntary restructuring plan, which includes a debtor-in-possession credit facility of $13 million, provided by sponsoring Senior and Subordinated Noteholders, to support the company's operations during the restructuring process. The plan also proposes a new-money equity capital raise of at least $9 million. ProSomnus aims to reorganize its equity structure, with new common equity to be distributed to Subordinated Secured Noteholders, diluting existing equity holders who are expected to experience a complete loss. The company's common stock and warrants were delisted from Nasdaq on April 24, 2024, and are now traded over-the-counter. The restructuring is subject to court approval, with the company operating as a debtor in possession and seeking to continue business operations as usual. The company cautions that trading in its securities is highly speculative and poses substantial risks during the Chapter 11 process.
On May 7, 2024, ProSomnus, Inc., a medical technology company, filed for Chapter 11 bankruptcy and entered into a Restructuring Support Agreement (RSA) with its affiliates, subsidiaries, and certain note holders. The RSA outlines a voluntary restructuring plan, which includes a debtor-in-possession credit facility of $13 million, provided by sponsoring Senior and Subordinated Noteholders, to support the company's operations during the restructuring process. The plan also proposes a new-money equity capital raise of at least $9 million. ProSomnus aims to reorganize its equity structure, with new common equity to be distributed to Subordinated Secured Noteholders, diluting existing equity holders who are expected to experience a complete loss. The company's common stock and warrants were delisted from Nasdaq on April 24, 2024, and are now traded over-the-counter. The restructuring is subject to court approval, with the company operating as a debtor in possession and seeking to continue business operations as usual. The company cautions that trading in its securities is highly speculative and poses substantial risks during the Chapter 11 process.
2024年5月7日，医疗技术公司ProSomnus, Inc. 申请了第11章破产，并与其关联公司、子公司和某些票据持有人签订了重组支持协议（RSA）。RSA概述了一项自愿重组计划，其中包括由担保的优先和次级票据持有人提供的1300万美元债务人持股信贷额度，以支持公司在重组过程中的运营。该计划还提议筹集至少900万美元的新资金股权。ProsomNUS旨在重组其股权结构，向次级有担保票据持有人分配新的普通股，从而稀释预计将遭受全部亏损的现有股权持有人。该公司的普通股和认股权证于2024年4月24日从纳斯达克退市，现在在场外交易。重组须经法院批准，公司以债务人的身份经营，并寻求照常经营业务。该公司警告说，其证券交易具有高度投机性，在第11章过程中构成重大风险。
2024年5月7日，医疗技术公司ProSomnus, Inc. 申请了第11章破产，并与其关联公司、子公司和某些票据持有人签订了重组支持协议（RSA）。RSA概述了一项自愿重组计划，其中包括由担保的优先和次级票据持有人提供的1300万美元债务人持股信贷额度，以支持公司在重组过程中的运营。该计划还提议筹集至少900万美元的新资金股权。ProsomNUS旨在重组其股权结构，向次级有担保票据持有人分配新的普通股，从而稀释预计将遭受全部亏损的现有股权持有人。该公司的普通股和认股权证于2024年4月24日从纳斯达克退市，现在在场外交易。重组须经法院批准，公司以债务人的身份经营，并寻求照常经营业务。该公司警告说，其证券交易具有高度投机性，在第11章过程中构成重大风险。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

独立文件3

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息